New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
14:28 EDTINOInovio not seeking partner for VGX-3100 right now, says Maxim
Maxim noted that Inovio management indicated it plans to initiate a pivotal phase III study for VGX-3100 in early 2016 and estimated that a pivotal program should cost about $100M. The firm also noted that Inovio is not seeking a partner on the drug right now and that the pivotal trial could move up depending on the company's meeting with the FDA. Maxim maintains a Buy rating and $18 price target on Inovio.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
08:06 EDTINOInovio appoints Zane Yang as VP, Clinical Development, Oncology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use